Insulet Reports Fourth Quarter and Full Year 2016 Financial Results

16:01 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Fourth Quarter Revenue of $103.6 Million, up 24% Year-Over-Year; Full Year 2016 Revenue of $367.0 Million, up 39% Year-Over Year, Exceeds Expectations Fourth Quarter Gross Margin Improves to 58.8%; Full Year 2016 Gross ...

Other Sources for this Article

Investor Relations and Media Contact:
Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications


More From BioPortfolio on "Insulet Reports Fourth Quarter and Full Year 2016 Financial Results"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...